IL-23 can induce IL-17 production by tumor-resident immune cells, including CD4+ Th17 cells, natural killer T (NKT) cells, γδ T cells and CD8+ cytotoxic T lymphocytes (CTLs). Here, IL17A is linked to neoplasm.